MGC Pharma adds expertise to its board as it progresses toward becoming a major cannabis biopharma

Special Report: MGC Pharma has welcomed a European corporate and pharmaceutical industry veteran as it reaffirms its commitment to become a leading European cannabis-focused bio-pharma.

This morning, the company (ASX:MXC) announced Dr Stephen Parker as Non-Executive Director.

Dr Parker brings more than 30 years’ experience to the MXC board, including an extensive network of connections within the pharmaceutical and investment industries.

His experience has primarily focused on the pharmaceutical and biotechnology sectors in the UK, Europe and North America, which should make for a good fit at MXC, which is working toward becoming a leading bio-pharma company within the medicinal cannabis sector, supplying treatments for patients in those same regions.

Dr Parker holds a number of board positions at top UK listed Biopharma companies including AIM-listed oncology therapeutics company Sareum Holdings (LON: SAR) and RNA-therapeutics focussed company, Silence Therapeutics Plc (LON: SLN).

Part of a broader strategy

... read more at: